Methanesulfonamide, N-(4-((((((4-(1,1-dimethylethyl)phenyl)methyl)amino)thioxomethyl)amino)methyl)-2-methoxyphenyl)- | 623166-14-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methanesulfonamide, N-(4-((((((4-(1,1-dimethylethyl)phenyl)methyl)amino)thioxomethyl)amino)methyl)-2-methoxyphenyl)-
• 英文别名: 1-[(4-tert-butylphenyl)methyl]-3-[[4-(methanesulfonamido)-3-methoxyphenyl]methyl]thiourea
• CAS: 623166-14-3
• 化学式: C₂₁H₂₉N₃O₃S₂
• 分子量: 435.6
• InChiKey: QGFPXWPVMTWSAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Oral delivery of peptide pharmaceutical compositions
  申请人：Mehta M. Nozer

  公开号：US20050282756A1

  公开（公告）日：2005-12-22

  Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.

  通过将一种药物组合物与一种吸收促进剂相结合，向肠道定向释放多肽，可提高口服多肽活性剂的生物利用度。将组合物置于耐酸保护载体中，使本发明的成分通过胃的运输，可进一步显著提高生物利用率。组合物还可以选择性地加入足量的 pH 值降低剂，以降低局部肠道的 pH 值。所有成分与肽一起释放到肠道中。
• ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS
  申请人：Unigene Laboratories, Inc.

  公开号：EP1755633A1

  公开（公告）日：2007-02-28
• US8835377B2
  申请人：——

  公开号：US8835377B2

  公开（公告）日：2014-09-16
• US9504727B2
  申请人：——

  公开号：US9504727B2

  公开（公告）日：2016-11-29
• [EN] ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS<br/>[FR] ADMINISTRATION PAR VOIE ORALE DE COMPOSITIONS PHARMACEUTIQUES PEPTIDIQUES
  申请人：UNIGENE LAB INC

  公开号：WO2006007332A1

  公开（公告）日：2006-01-19

  Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.